Literature DB >> 22174427

Don't get boxed in: commentary on the visual inspection practices to assess exposure-response relationships from binary clinical variables.

Shailly Mehrotra1, Jeffry Florian, Jogarao Gobburu.   

Abstract

Mesh：

Year:  2011        PMID： 22174427     DOI： 10.1177/0091270011429568

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  6 in total

1.  Prediction of H3 receptor occupancy diurnal fluctuations using population modeling and simulation with focus on guiding dose selection in a Phase IIa study.

Authors:  Emma Boström; Yi-Fang Cheng; Niclas Brynne; Märta Segerdahl
Journal:  Pharm Res       Date:  2014-02       Impact factor: 4.200

2.  Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.

Authors:  Shailly Mehrotra; Mathangi Gopalakrishnan; Jogarao Gobburu; Jiuping Ji; Jacqueline M Greer; Richard Piekarz; Judith E Karp; Keith W Pratz; Michelle A Rudek
Journal:  Clin Cancer Res       Date:  2017-07-27       Impact factor: 12.531

3.  Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.

Authors:  Jing Niu; Christie Scheuerell; Shailly Mehrotra; Sharon Karan; Shannon Puhalla; Brian F Kiesel; Jiuping Ji; Edward Chu; Mathangi Gopalakrishnan; Vijay Ivaturi; Jogarao Gobburu; Jan H Beumer
Journal:  J Clin Pharmacol       Date:  2017-04-07       Impact factor: 3.126

4.  Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.

Authors:  Renu Singh; Shailly Mehrotra; Mathangi Gopalakrishnan; Ivana Gojo; Judith E Karp; Jacqueline M Greer; Alice Chen; Richard Piekarz; Brian F Kiesel; Jogarao Gobburu; Michelle A Rudek; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2018-11-20       Impact factor: 3.333

5.  Patient-Level Adverse Event Patterns in a Single-Institution Study of the Multi-Kinase Inhibitor Sorafenib.

Authors:  S Karovic; E F Shiuan; S Q Zhang; H Cao; M L Maitland
Journal:  Clin Transl Sci       Date:  2016-07-21       Impact factor: 4.689

Review 6.  A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.

Authors:  Dan Lu; Tong Lu; Mark Stroh; Richard A Graham; Priya Agarwal; Luna Musib; Chi-Chung Li; Bert L Lum; Amita Joshi
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-25       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.